Henry Stewart Talks

The Biomedical & Life Sciences Collection

Online Seminars By Leading World Experts
Search

Talk: Advances in asthma: the role of exhaled nitric oxide... (61 min)

 Loading...

This talk is not yet available, however should be within a few days.

We apologize for the inconvenience.

- Henry Stewart Talks

X Navigable Slide Index
  1. Introduction
  2. GINA definition of asthma
  3. Inflammatory subtypes in asthma
  4. Airway inflammation - eosinophils vs. FeNO
  5. FeNO levels vs. eosinophilic airway inflammation
  6. FeNO levels vs. neutrophilic airway inflammation
  7. FeNO and eosinophils
  8. FeNO in healthy subjects
  9. Factors affecting FeNO
  10. Factors affecting FeNO: genetic vs. environmental
  11. Cut-points for interpreting FeNO
  12. Exhaled NO and asthma diagnosis
  13. Exhaled NO in bronchial asthma
  14. FeNO in healthy/untreated asthmatic subjects
  15. Diagnosing asthma - conventional tests
  16. Diagnosing asthma: FeNO and sputum eosinophils
  17. Combined FeNO and spirometry
  18. FeNO as a diagnostic test
  19. Performance characteristics of FeNO
  20. FeNO and cough diagnosis (1)
  21. FeNO and cough diagnosis (2)
  22. FeNO in the assessment of cough
  23. Using sputum cell counts for asthma diagnosis
  24. Rat challenge - FeNO measurement
  25. Laboratory animal allergy (LAA)
  26. NO and steroid responsiveness
  27. FeNO measurements in anti-inflammatory therapy
  28. Sputum eosinophils and ICS in asthma (1)
  29. Sputum eosinophils and oral prednisone in COPD
  30. Sputum neutrophils and ICS in asthma (2)
  31. Hypothesis
  32. FEV1 change with fluticasone vs. baseline FeNO
  33. PC20AMP improvement with fluticasone (1)
  34. PC20AMP improvement with fluticasone (2)
  35. Predicting steroid response: EA vs. NEA
  36. Steroid responsiveness and non-responsiveness
  37. The clinical questions
  38. Heterogeneity of treatment response
  39. The PACT study
  40. The GOAL study
  41. FeNO and treatment requirements
  42. FeNO and steroid therapy
  43. Predicting relapse of asthma after ICS withdrawal
  44. Predicting outcome of ICS dose reduction
  45. FeNO as a prognostic guide
  46. Using FeNO to optimize steroid requirements
  47. Sputum cell counts and asthma management
  48. NO and inhaled corticosteroid (1)
  49. NO and inhaled corticosteroid (2)
  50. Cut points and their origin
  51. The MAP study
  52. The MAP study - FeNO algorithm
  53. The MAP study - results (1)
  54. The MAP study - results (2)
  55. FeNO measurements - using reference values
  56. Reference equations for FeNO
  57. Predicted versus absolute values (1)
  58. Predicted versus absolute values (2)
  59. High FeNO despite steroid treatment in children
  60. High FeNO - conclusions
  61. Using FeNO measurements to monitor asthma
  62. Exhaled NO and asthma control
  63. FeNO and asthma control (1)
  64. Using biomarkers - the timing of signal change
  65. Defining a 'clinically meaningful change'
  66. FeNO and asthma control (2)
  67. Predicting loss of control
  68. Biomarker use in complex asthma: discordance
  69. Dysfunctional breathing and ICS doses
  70. Patient K.P.
  71. Patient J.S.
  72. Applying FeNO measurements: summary (1)
  73. Applying FeNO measurements: summary (2)
  74. Conclusions
  75. END
1 2 3 4

We hope you have enjoyed this limited-length demo talk

  • Would you like to recommend that your librarian or other responsible officer takes out a subscription to The Biomedical & Life Sciences Collection?
  • Would you like to apply for a free trial of the entire Biomedical & Life Sciences Collection?
Recommend to Librarian       Apply for Free Trial       Replay Talk

SHARE THIS TALK

Email via Local Program (e.g. Outlook) Email via the Web Share with Facebook Tweet on Twitter Share with Gmail Share with VKontakte Share with LinkedIn More

DETAILED SLIDE INDEX

  1. 1. Introduction
  2. 2. GINA definition of asthma
  3. 3. Inflammatory subtypes in asthma
  4. 4. Airway inflammation - eosinophils vs. FeNO
  5. 5. FeNO levels vs. eosinophilic airway inflammation
  6. 6. FeNO levels vs. neutrophilic airway inflammation
  7. 7. FeNO and eosinophils
  8. 8. FeNO in healthy subjects
  9. 9. Factors affecting FeNO
  10. 10. Factors affecting FeNO: genetic vs. environmental
  11. 11. Cut-points for interpreting FeNO
  12. 12. Exhaled NO and asthma diagnosis
  13. 13. Exhaled NO in bronchial asthma
  14. 14. FeNO in healthy/untreated asthmatic subjects
  15. 15. Diagnosing asthma - conventional tests
  16. 16. Diagnosing asthma: FeNO and sputum eosinophils
  17. 17. Combined FeNO and spirometry
  18. 18. FeNO as a diagnostic test
  19. 19. Performance characteristics of FeNO
  20. 20. FeNO and cough diagnosis (1)
  21. 21. FeNO and cough diagnosis (2)
  22. 22. FeNO in the assessment of cough
  23. 23. Using sputum cell counts for asthma diagnosis
  24. 24. Rat challenge - FeNO measurement
  25. 25. Laboratory animal allergy (LAA)
  26. 26. NO and steroid responsiveness
  27. 27. FeNO measurements in anti-inflammatory therapy
  28. 28. Sputum eosinophils and ICS in asthma (1)
  29. 29. Sputum eosinophils and oral prednisone in COPD
  30. 30. Sputum neutrophils and ICS in asthma (2)
  31. 31. Hypothesis
  32. 32. FEV1 change with fluticasone vs. baseline FeNO
  33. 33. PC20AMP improvement with fluticasone (1)
  34. 34. PC20AMP improvement with fluticasone (2)
  35. 35. Predicting steroid response: EA vs. NEA
  36. 36. Steroid responsiveness and non-responsiveness
  37. 37. The clinical questions
  38. 38. Heterogeneity of treatment response
  39. 39. The PACT study
  40. 40. The GOAL study
  41. 41. FeNO and treatment requirements
  42. 42. FeNO and steroid therapy
  43. 43. Predicting relapse of asthma after ICS withdrawal
  44. 44. Predicting outcome of ICS dose reduction
  45. 45. FeNO as a prognostic guide
  46. 46. Using FeNO to optimize steroid requirements
  47. 47. Sputum cell counts and asthma management
  48. 48. NO and inhaled corticosteroid (1)
  49. 49. NO and inhaled corticosteroid (2)
  50. 50. Cut points and their origin
  51. 51. The MAP study
  52. 52. The MAP study - FeNO algorithm
  53. 53. The MAP study - results (1)
  54. 54. The MAP study - results (2)
  55. 55. FeNO measurements - using reference values
  56. 56. Reference equations for FeNO
  57. 57. Predicted versus absolute values (1)
  58. 58. Predicted versus absolute values (2)
  59. 59. High FeNO despite steroid treatment in children
  60. 60. High FeNO - conclusions
  61. 61. Using FeNO measurements to monitor asthma
  62. 62. Exhaled NO and asthma control
  63. 63. FeNO and asthma control (1)
  64. 64. Using biomarkers - the timing of signal change
  65. 65. Defining a 'clinically meaningful change'
  66. 66. FeNO and asthma control (2)
  67. 67. Predicting loss of control
  68. 68. Biomarker use in complex asthma: discordance
  69. 69. Dysfunctional breathing and ICS doses
  70. 70. Patient K.P.
  71. 71. Patient J.S.
  72. 72. Applying FeNO measurements: summary (1)
  73. 73. Applying FeNO measurements: summary (2)
  74. 74. Conclusions
  75. 75. END

RELATED TALKS

Play 'Recent advances in asthma genetics'
Recent advances in asthma genetics More info
Prof. Miriam Moffatt

TOPICS COVERED IN THIS TALK

  • Incidence of asthma
  • Environment and genetic causes
  • Disease identification prior to completion of sequencing of the human genome
  • Genome Wide Association Study (GWAS)
  • Omic technologies including global gene expression
  • GABRIEL and Asthma susceptibility genes identified by GWAS
  • Asthma and infection
  • 16S rRNA and metagenomics
  • What next
Play 'Advances in asthma: airway inflammation'
Advances in asthma: airway inflammation More info
Prof. William Busse

TOPICS COVERED IN THIS TALK

  • Airway inflammation is a complex, interactive, redundant immune response
  • Components of inflammation in asthma
  • "Traditional" inflammatory cells in airway inflammation
  • Mast cells and eosinophils
  • Lymphocytes
  • Using monoclonal antibodies to gain insight into the clinical significance of inflammation in asthma
  • IgE, IL-5, and IL-13
  • The diversity of patterns of inflammation in asthma
  • Personalized medicine
Play 'The role of mast cells in asthma'
The role of mast cells in asthma More info
Prof. Peter Bradding

TOPICS COVERED IN THIS TALK

  • Mast cell biology
  • Mast cell cytokines
  • Mast cell activation in asthma
  • Mast cell tissue microlocalisation in asthma
  • Mast cell-airway smooth muscle interactions as a key feature of asthma
Play 'Management of acute exacerbations of asthma'
Management of acute exacerbations of asthma More info
Dr. Chris Fanta

TOPICS COVERED IN THIS TALK

  • Asthma prevention, assessment, treatment and disposition
  • Risk factors and physical findings in severe asthma attacks
  • Treatments: Steroids, MDI, Nebulizer, Beta-agonists, Bronchodilators, Magnesium, Heliox & Antibiotics
  • Unproven and unconventional therapies
  • Rationale for in-hospital treatment and indications for admission
  • Indications for intubation & mechanical ventilation
  • Discharge criteria and patient education prior to hospital discharge
Play 'Management of "difficult asthma"'
Management of "difficult asthma" More info
Prof. Elisabeth Bel

TOPICS COVERED IN THIS TALK

  • Difficult asthma and severe refractory asthma
  • Heterogeneous reasons for severe asthma
  • "High dose" therapy
  • Treatments for severe asthma
  • Eosinophilic vs. non eosinophilic inflammation
  • Effect of CRS treatment on asthma
  • Mechanism of action of anti IgE
  • Effect of anti IgE on severe asthma exacerbations
  • Effect of anti IL-5 (mepolizumab) on spontaneous asthma exacerbations
  • Clarithromycin in neutrophilic asthma
  • Macrolides in chronic stable asthma
  • Mechanisms of asthma severity in obese patients
  • Implications for the future

USE THIS TALK IN YOUR COURSE

TALK'S CITATION

Taylor, R. (2011), "Advances in asthma: the role of exhaled nitric oxide in the assessment and management of asthma ", in Barnes, P. (ed.), Advances in Asthma: New mechanisms, management strategies and treatments, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/?t=BL1403023)

RELATED SERIES

Advances in Chronic Obstructive Pulmonary Disease (COPD)
New mechanisms, management strategies and treatments
Stem Cells
Recent advances in understanding and utilizing
Introduction to Human Genetics
Fundamentals and latest advances
Monoclonal Antibodies as Therapeutic Agents
Fundamentals, Therapeutic Applications and Latest Advances
Welcome, Guest
Login  
Apply for Free Trial Recommend to Librarian Keep Me Updated
Close
Undergraduate Lectures  »

ABOUT THIS TALK

Speaker(s)

Prof. Robin Taylor Show Biography

SPEAKER BIOGRAPHY

Prof. Robin Taylor – University of Otago, New Zealand

D. Robin Taylor is Professor of Respiratory Medicine at the Dunedin School of Medicine, University of Otago, New Zealand. His research is clinically focused, and has included the adverse effects of beta-agonist drugs in asthma. More recently, his group have researched the clinical applications of exhaled nitric oxide as a complementary tool in the assessment of undiagnosed respiratory symptoms as well as patients with established asthma and COPD.

Publication Date

December, 2011

Topics Covered

Exhaled nitric oxide (NO) in asthma... more

TOPICS COVERED IN THIS TALK

  • Exhaled nitric oxide (NO) in asthma
  • The relationship between exhaled NO and airway inflammation
  • Use of exhaled NO in diagnosis of respiratory symptoms
  • Exhaled NO as a predictor of steroid responsiveness
  • Strengths and weaknesses use of exhaled NO in monitoring asthma
  • Guideline for the clinical application of exhaled NO

Series

Advances in Asthma

OTHER TALKS IN THIS SERIES

EPIDEMIOLOGY AND RISK FACTORS
Play '1. The changing prevalence of asthma'
1. The changing prevalence of asthma More info
Dr. Deborah Jarvis

TOPICS COVERED IN THIS TALK

  • Measuring asthma prevalence in community studies
  • Geographical variation in prevalence of disease
  • Early studies showing an increase in disease
  • More recent studies of time trends
  • Possible reasons for changing prevalence of disease
Play '2. Recent advances in asthma genetics'
2. Recent advances in asthma genetics More info
Prof. Miriam Moffatt

TOPICS COVERED IN THIS TALK

  • Incidence of asthma
  • Environment and genetic causes
  • Disease identification prior to completion of sequencing of the human genome
  • Genome Wide Association Study (GWAS)
  • Omic technologies including global gene expression
  • GABRIEL and Asthma susceptibility genes identified by GWAS
  • Asthma and infection
  • 16S rRNA and metagenomics
  • What next
Play '3. Asthma: an epidemic caused by epigenetics?'
3. Asthma: an epidemic caused by epigenetics? More info
Prof. David Schwartz

TOPICS COVERED IN THIS TALK

  • Genetic and biological determinants of diseases influenced by the environment
  • Epigenetics
  • Epigenetic mechanisms can be influenced by environmental exposures and aging
  • Histone modifications and innate immunity
  • Asthma is a major public health problem
  • Epigenetics and airway immunology
  • DNA methylation changes and asthma
  • Runx3 and airway disease
  • In utero folate supplementation and asthma
  • Sib pair asthma study
  • Preliminary analysis
  • Global methylation patterns: asthmatics vs. nonasthmatics
  • Hypomethylation of GATA3 or MUC5B is associated with asthma in concordant sib pairs
  • Hypermethylation of NOS2 is associated with concordant asthma
  • Asthma: an epidemic caused by epigenetics?
Play '4. Diet and asthma'
4. Diet and asthma More info
Prof. Lewis Smith

TOPICS COVERED IN THIS TALK

  • Increase in asthma worldwide
  • Parallel environmental changes including diet
  • Assessing role of diet is complex
  • Focus on antioxidant vitamins, vitamin D and genistein
Play '5. Obesity and asthma'
5. Obesity and asthma More info
Dr. Anne Dixon

TOPICS COVERED IN THIS TALK

  • Obesity as a risk factor for asthma
  • Unique characteristics of asthma in the obese
  • Role of comorbidities in asthma in the obese
Play '6. Occupational asthma: management beyond the textbooks'
6. Occupational asthma: management beyond the textbooks More info
Prof. Paul Cullinan

TOPICS COVERED IN THIS TALK

  • A wide variety of agents can cause occupational asthma
  • A case study of possible occupational asthma
  • Important points to consider for potential occupational asthma sufferers; diagnosis and approach
  • Identification and care of patients
CLINICAL PHENOTYPES
Play '7. The origins of asthma'
7. The origins of asthma More info
Prof. Peter Sly

TOPICS COVERED IN THIS TALK

  • Asthma is a multifactorial condition
  • Asthma as a "Syndrome"
  • Causes of asthma: genetic and environmental
  • Development of asthma
  • Growth of respiratory system
  • Maturation of the immune system
  • Prenatal exposures which cause asthma
  • Asthma risk factors
  • Considering atopy when assessing asthma risk
Play '8. Asthma phenotypes in children'
8. Asthma phenotypes in children More info
Prof. Andrew Bush

TOPICS COVERED IN THIS TALK

  • Severe asthma
  • Getting the basics right
  • Rarity of genuine severe therapy resistant asthma
  • Differences between childhood and adult asthma
  • Protocol driven investigations to determine nature of any inflammation
  • Phenotype discordance
  • Steroid responsiveness
  • Presence of fixed airflow obstruction
  • Exacerbating phenotype particularly difficult to treat
Play '9. Smoking asthmatics'
9. Smoking asthmatics More info
Prof. Neil Thomson

TOPICS COVERED IN THIS TALK

  • High prevalence rates of smoking in asthma
  • Detrimental effects of smoking on clinical outcomes
  • Impaired response to corticosteroids
  • Mechanisms of adverse effects
  • Management includes smoking cessation, but optimum drug therapy not established
Play '10. Aspirin exacerbated respiratory disease'
10. Aspirin exacerbated respiratory disease More info
Prof. Chris Corrigan

TOPICS COVERED IN THIS TALK

  • Clinical features
  • AERD as a disease of excessive leukotriene production
  • Alterations in eicosanoid metabolism
  • The protective role of Prostaglandin E2 (PGE2)
  • Reduced PGE2 signalling as a mechanism for AERD
  • The PGE2 receptor EP2 as a molecular target
MECHANISMS OF ASTHMA
Play '11. Advances in asthma: airway inflammation'
11. Advances in asthma: airway inflammation More info
Prof. William Busse

TOPICS COVERED IN THIS TALK

  • Airway inflammation is a complex, interactive, redundant immune response
  • Components of inflammation in asthma
  • "Traditional" inflammatory cells in airway inflammation
  • Mast cells and eosinophils
  • Lymphocytes
  • Using monoclonal antibodies to gain insight into the clinical significance of inflammation in asthma
  • IgE, IL-5, and IL-13
  • The diversity of patterns of inflammation in asthma
  • Personalized medicine
Play '12. The role of mast cells in asthma'
12. The role of mast cells in asthma More info
Prof. Peter Bradding

TOPICS COVERED IN THIS TALK

  • Mast cell biology
  • Mast cell cytokines
  • Mast cell activation in asthma
  • Mast cell tissue microlocalisation in asthma
  • Mast cell-airway smooth muscle interactions as a key feature of asthma
Play '13. Dendritic cells in asthma'
13. Dendritic cells in asthma More info
Prof. Bart Lambrecht

TOPICS COVERED IN THIS TALK

  • The global immune response of the lungs
  • Dendritic cells (DCs): localisation, trafficking, probing for antigen, activation, behaviour in airways during asthma and inflammation
  • Controlling responsiveness to the node T cell area & Immunological synapse formation
  • Peptide presentation by MHC class II molecules
  • Cascade of costimulatory events
  • Th2 lymphocytes role in airway inflammation
  • Targeting DCs
  • Allergen exposure activation
  • Epithelial vs. DC expression of TLR4
  • Metabolic alterations
  • Uric acid and antigen sensitisation in mice
  • DC depletion
  • Basement membrane thickening in asthma
  • Model of chronic airway remodelling in the lungs
  • Collagen deposition & antigen uptake/recognition
  • Presentation of neoantigen
Play '14. The airway smooth muscle in asthma'
14. The airway smooth muscle in asthma More info
Prof. Judith Black

TOPICS COVERED IN THIS TALK

  • Remodelling of the asthmatic airway
  • Airway smooth muscle (ASM)
  • increased deposition of matrix proteins
  • Asthma increases ASM
  • Characteristics of ASM cells in non-asthmatics
  • Characteristics of ASM in asthmatics
  • ASM produces extracellular matrix (ECM) proteins
  • Differences in ECM in asthmatics
  • Fibulin-1 in asthma
  • Fibulin as a therapeutic target
Play '15. Role of virus infection in asthma - Part 1'
15. Role of virus infection in asthma - Part 1 More info
Prof. Sebastian Johnston

TOPICS COVERED IN THIS TALK

  • Role of viruses in asthma exacerbations
  • Huge clinical problem unmet by current therapies
  • Viruses major cause in all age groups
  • Deficient anti-viral immunity in asthma
  • Potential therapies; specific anti-virals and broad-spectrum approaches
Play '16. Role of virus infection in asthma - Part 2'
16. Role of virus infection in asthma - Part 2 More info
Prof. Sebastian Johnston

TOPICS COVERED IN THIS TALK

  • Role of viruses in development of asthma
  • Association between early life severe lower respiratory viral illness and later development of asthma
  • Is this association due to a common risk factor, a causal factor, or both?
  • Future studies
Play '17. Severe asthma: characterisation, mechanisms  & treatment'
17. Severe asthma: characterisation, mechanisms & treatment More info
Prof. Fan Chung

TOPICS COVERED IN THIS TALK

  • Definition and characterisation
  • From difficult-to-treat asthma to severe asthma
  • Phenotypes and characteristics
  • Current treatment modalities
  • Chronic airflow obstruction
  • Corticosteroid insensitivity
  • Future treatments: specific targets for specific phenotypes
Play '18. Steroid resistance in asthma: mechanisms and potential therapies'
18. Steroid resistance in asthma: mechanisms and potential therapies More info
Prof. Ian Adcock

TOPICS COVERED IN THIS TALK

  • Overview of asthma pathophysiology
  • Patterns of severe refractory asthma
  • Methods to improve steroid efficacy in severe asthma
  • Mechanisms that induce steroid insensitivity; Th2 cytokines, IL-17 and infections
  • Pathophysiology of severe treatment refractory asthma
  • Novel anti-inflammatory approaches
  • Can new combinations of drugs reverse steroid insensitivity in severe asthma?
Play '19. Macrophage in asthma'
19. Macrophage in asthma More info
Prof. Douglas Robinson

TOPICS COVERED IN THIS TALK

  • Contributing factors to asthma include abnormal epithelium, predominant Th2 cytokines, and inappropriate repair leading to airway remodeling
  • Alternative activation of macrophages (via IL-4 and IL-13) leads to chitinase production
  • Interstitial macrophages may have regulatory role (via IL-10)
  • IL-13 may be a key cytokine in activation of airway macrophages
  • IL-13 amplifies features of asthma such as airway hyperresponsiveness and mucus production
DIAGNOSIS OF ASTHMA
Play '20. Physiology of asthma and involvement of small airways'
20. Physiology of asthma and involvement of small airways More info
Prof. Charles G. Irvin

TOPICS COVERED IN THIS TALK

  • Physiology of asthma, a syndrome defined by lung dysfunction
  • Airflow limitation
  • Small airways
  • Reversibility of airflow limitation
  • Periodicity and variability of airflow limitation
  • Airways hyperresponsiveness
Play '21. Induced sputum in asthma'
21. Induced sputum in asthma More info
Prof. Antonio Spanevello

TOPICS COVERED IN THIS TALK

  • Induced Sputum: facilities and procedure
  • Induced Sputum as a biomarker of airway disease in asthma
  • Comparison with other techniques
  • Reference values and comparison between healthy and patients
  • Induced sputum in asthma: clinical implications
Now Playing
22. Advances in asthma: the role of exhaled nitric oxide in the assessment and management of asthma
Prof. Robin Taylor
THERAPY AND MANAGEMENT
Play '23. The management of chronic asthma'
23. The management of chronic asthma More info
Prof. Mark Fitzgerald

TOPICS COVERED IN THIS TALK

  • Importance of reviewing patient's history
  • Identification of potential environmental factors
  • Patients with uncontrolled asthma may require anti-inflammatory medications with inhaled corticosteroids (ICS) being the standard treatment
  • Asthmatics on ICS with uncontrolled asthma may require adjunct therapy such as a long acting beta agonist and or a leukotriene antagonist
  • Education program and written action plan
Play '24. Inhaled corticosteroids and beta2-agonists'
24. Inhaled corticosteroids and beta2-agonists More info
Dr. Omar Usmani

TOPICS COVERED IN THIS TALK

  • Asthma treatment guidelines
  • Pharmacology of inhaled corticosteroids and long-acting beta agonists
  • Clinical evidence for combination therapy in asthma
  • Molecular interactions between inhaled corticosteroids and long-acting beta agonists
Play '25. Management of "difficult asthma"'
25. Management of "difficult asthma" More info
Prof. Elisabeth Bel

TOPICS COVERED IN THIS TALK

  • Difficult asthma and severe refractory asthma
  • Heterogeneous reasons for severe asthma
  • "High dose" therapy
  • Treatments for severe asthma
  • Eosinophilic vs. non eosinophilic inflammation
  • Effect of CRS treatment on asthma
  • Mechanism of action of anti IgE
  • Effect of anti IgE on severe asthma exacerbations
  • Effect of anti IL-5 (mepolizumab) on spontaneous asthma exacerbations
  • Clarithromycin in neutrophilic asthma
  • Macrolides in chronic stable asthma
  • Mechanisms of asthma severity in obese patients
  • Implications for the future
Play '26. Management of acute exacerbations of asthma'
26. Management of acute exacerbations of asthma More info
Dr. Chris Fanta

TOPICS COVERED IN THIS TALK

  • Asthma prevention, assessment, treatment and disposition
  • Risk factors and physical findings in severe asthma attacks
  • Treatments: Steroids, MDI, Nebulizer, Beta-agonists, Bronchodilators, Magnesium, Heliox & Antibiotics
  • Unproven and unconventional therapies
  • Rationale for in-hospital treatment and indications for admission
  • Indications for intubation & mechanical ventilation
  • Discharge criteria and patient education prior to hospital discharge
Play '27. Non-pharmacological treatments for asthma'
27. Non-pharmacological treatments for asthma More info
Prof. Neil Thomson

TOPICS COVERED IN THIS TALK

  • Non-pharmacological treatments in the management of patients with asthma
  • Avoidance measures
  • Dietary measures
  • Immunotherapy
  • Bronchial thermoplasty
  • Physical therapies
  • Psychological treatments
  • Complementary therapies
  • Need for high quality research to assess the effectiveness of some interventions
Play '28. Asthma: beyond the prescription'
28. Asthma: beyond the prescription More info
Prof. Martyn Partridge

TOPICS COVERED IN THIS TALK

  • Patient/health professional contact
  • The role of the asthma patients
  • Denial of the diagnosis
  • Knowledge of asthma amongst the parents
  • Levels of asthma control
  • How patients perceive their asthma
  • Treatment guidelines
  • Assessing patients' preferences
  • Defining the ideal relationship with a specialist
  • Involvement in treatment decisions
  • British asthma guidelines
  • Compliance of practices with recommendations
  • Written asthma action plans
  • Software
  • Literacy and health
  • The use of technology
  • Sources of information
  • Better compliance with electronic reminders
  • Use of non technological adjuncts
  • Consultation is important for patients
Play '29. New drugs for asthma'
29. New drugs for asthma More info
Prof. Peter Barnes

TOPICS COVERED IN THIS TALK

  • Improvements in existing therapies have been the main approach
  • New classes of drug in development
  • Upcoming oral and inhaled therapies that target inflammation in asthma
  • Patients with severe disease
  • Inflammation in severe asthma is usually corticosteroid insensitive
Play '30. Anti-IgE therapy for asthma'
30. Anti-IgE therapy for asthma More info
Dr. Andrew Menzies-Gow

TOPICS COVERED IN THIS TALK

  • Anti-IgE therapy for asthma
  • Allergy can be associated with severe asthma
  • Omalizumab, a monoclonal anti-IgE, is the first targeted biological therapy for severe asthma with good clinical efficacy
  • Patient selection, drug administration and length of treatment are discussed

We use cookies on this site to enhance your user experience

By clicking any link on this page you are giving your consent for us to set cookies.